In order to develop a possible C-X-C chemokine receptor type 4 (CXCR4) imaging agent for oncological scintigraphy, [62Zn]labeled 1,1′-[1,4-Phenylenebis(methylene)] bis-1,4,8,11-tetraazacyclo- tetradecane ([62Zn]-AMD3100) was prepared using in-house made [62Zn]ZnCl2 and AMD-3100 for 1h at 50C (radiochemical purity: >97% ITLC, >96% HPLC, specific activity: 20-22 GBq/mmol) in acetate buffer. The complex showed highly hydrophilic properties (log P. -1.114). Stability of the complex was checked in presence of human serum (37ºC) and in final formulation for 1 day. The biodistribution of the labeled compound in vital organs of wild-type Sprague-Dawdley rats were determined and compared with that of free Zn2+ cation up to 6h. Co-incidence imaging of the complex was consistent with the distribution data up to 3h. The complex can be a possible in vivo generator compound for PET imaging in CXCR4 positive tumors.
Tehran University of Medical Sciences
Radiosynthesis and biodistribution studies of [62Zn/62Cu]-Plerixafor complex as a novel in vivo PET generator for chemokine receptor imaging
Authors: Aghanejad A, Jalilian AR, Fazaeli Y, Beiki D, Fateh B, khalaj A,
Keywords: 62Zn, Production, AMD-3100, Radiolabeling, Biodistribution, Coincidence imaging
J Radioanal Nucl Chem, Vol.299, No., 2014,Page:1635-1644